Biogen Inc (BIIB)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $37.46B
Last updated: Nov 17, 2026 at 11:04 AM ET
Biogen Inc (BIIB) Earnings: Report Dates and Results
Biogen (BIIB) is expected to report earnings on Feb 4, 2027. In the quarter ended Sep 30, 2026, Biogen reported EPS of $2.62, above the $2.06 estimate. It beat the EPS estimate in each of the last 18 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BIIB has an expected report date of Feb 4, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 41.2% above the $1.99 reported for the quarter ended Dec 31, 2025.
BIIB Earnings Call
The latest BIIB earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BIIB beat 37 and missed 3. Revenue for the quarter ended Sep 30, 2026 was $2.80B, up 10.7% from $2.53B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.62 | $2.06 | $1.44 - $2.31 | +27.18% | Beat | -45.5% | 27 | 2 up, 2 down | Oct 28, 2026 | $2.80B |
| Jun 30, 2026 | $3.60 | $3.04 | -$21.10 - $3.80 | +18.42% | Beat | -34.2% | 27 | 1 up, 0 down | Jul 29, 2026 | $2.74B |
| Mar 31, 2026 | $3.57 | $2.89 | $1.45 - $4.68 | +23.53% | Beat | +18.2% | 28 | 4 up, 13 down | Apr 29, 2026 | $2.48B |
| Dec 31, 2025 | $1.99 | $1.62 | $1.31 - $2.24 | +22.84% | Beat | -42.2% | 26 | 9 up, 5 down | Feb 6, 2026 | $2.28B |
| Sep 30, 2025 | $4.81 | $3.88 | $3.18 - $4.60 | +23.97% | Beat | +17.9% | 26 | 8 up, 6 down | Oct 30, 2025 | $2.53B |
| Jun 30, 2025 | $5.47 | $3.88 | $3.59 - $4.12 | +40.98% | Beat | +3.6% | 26 | 2 up, 14 down | Jul 31, 2025 | $2.65B |
| Mar 31, 2025 | $3.02 | $2.95 | $1.94 - $4.03 | +2.37% | Beat | -17.7% | 24 | 1 up, 13 down | May 1, 2025 | $2.43B |
| Dec 31, 2024 | $3.44 | $3.36 | $2.77 - $3.68 | +2.38% | Beat | +4.2% | 26 | 2 up, 11 down | Feb 12, 2025 | $2.45B |
| Sep 30, 2024 | $4.08 | $3.79 | $3.52 - $4.35 | +7.65% | Beat | -6.4% | 25 | 6 up, 0 down | Oct 30, 2024 | $2.47B |
| Jun 30, 2024 | $5.28 | $4.03 | $3.46 - $6.04 | +31.02% | Beat | +31.3% | 27 | 8 up, 1 down | Aug 1, 2024 | $2.46B |
| Mar 31, 2024 | $3.67 | $3.46 | $3.06 - $3.96 | +6.07% | Beat | +7.9% | 28 | 9 up, 1 down | Apr 24, 2024 | $2.29B |
| Dec 31, 2023 | $3.30 | $3.18 | $2.75 - $3.86 | +3.77% | Beat | -18.5% | 27 | 9 up, 0 down | Feb 13, 2024 | $2.39B |
| Sep 30, 2023 | $4.36 | $3.98 | $3.11 - $4.50 | +9.55% | Beat | -8.6% | 25 | 6 up, 2 down | Nov 8, 2023 | $2.53B |
| Jun 30, 2023 | $4.02 | $3.76 | $3.07 - $4.16 | +6.91% | Beat | -23.4% | 25 | 6 up, 4 down | Jul 25, 2023 | $2.46B |
| Mar 31, 2023 | $3.40 | $3.28 | $2.16 - $3.88 | +3.66% | Beat | -6.1% | 24 | 2 up, 2 down | Apr 25, 2023 | $2.46B |
| Dec 31, 2022 | $4.05 | $3.48 | $3.17 - $4.18 | +16.38% | Beat | +19.5% | 26 | 10 up, 0 down | Feb 15, 2023 | $2.54B |
| Sep 30, 2022 | $4.77 | $4.13 | $3.57 - $4.81 | +15.50% | Beat | 0.0% | 26 | 7 up, 3 down | Oct 25, 2022 | $2.51B |
| Jun 30, 2022 | $5.25 | $4.07 | $3.24 - $4.75 | +28.99% | Beat | -7.6% | 26 | 4 up, 4 down | Jul 20, 2022 | $2.59B |
| Mar 31, 2022 | $3.62 | $4.36 | $3.52 - $5.36 | -16.97% | Miss | -32.2% | 25 | 8 up, 0 down | May 3, 2022 | $2.53B |
| Dec 31, 2021 | $3.39 | $3.37 | $2.88 - $4.14 | +0.59% | Beat | -26.0% | 28 | 7 up, 0 down | Feb 3, 2022 | $2.73B |
| Sep 30, 2021 | $4.77 | $4.10 | $3.65 - $4.69 | +16.34% | Beat | -46.0% | 23 | N/A | Oct 20, 2021 | $2.78B |
| Jun 30, 2021 | $5.68 | $4.60 | $3.73 - $5.31 | +23.48% | Beat | -44.6% | 25 | N/A | Jul 22, 2021 | $2.77B |
| Mar 31, 2021 | $5.34 | $4.94 | $4.05 - $5.89 | +8.10% | Beat | -41.6% | 24 | N/A | Apr 22, 2021 | $2.69B |
| Dec 31, 2020 | $4.58 | $4.80 | $4.14 - $7.14 | -4.58% | Miss | -45.1% | 28 | N/A | Feb 3, 2021 | $2.85B |
| Sep 30, 2020 | $8.84 | $8.05 | $7.61 - $8.99 | +9.81% | Beat | -3.6% | 28 | N/A | Oct 21, 2020 | $3.38B |
| Jun 30, 2020 | $10.26 | $8.00 | $7.09 - $9.07 | +28.25% | Beat | +12.1% | 25 | N/A | Jul 22, 2020 | $3.68B |
| Mar 31, 2020 | $9.14 | $7.69 | $5.63 - $8.65 | +18.86% | Beat | +30.9% | 28 | N/A | Apr 22, 2020 | $3.53B |
| Dec 31, 2019 | $8.34 | $8.08 | $6.47 - $9.32 | +3.22% | Beat | +19.3% | 29 | N/A | Jan 30, 2020 | $3.67B |
| Sep 30, 2019 | $9.17 | $8.27 | $7.80 - $9.15 | +10.88% | Beat | +23.9% | 27 | N/A | Oct 22, 2019 | $3.60B |
| Jun 30, 2019 | $9.15 | $7.53 | $6.74 - $8.11 | +21.51% | Beat | +57.8% | 27 | N/A | Jul 23, 2019 | $3.62B |
| Mar 31, 2019 | $6.98 | $6.96 | $6.38 - $7.47 | +0.29% | Beat | +15.4% | 25 | N/A | Apr 24, 2019 | $3.49B |
| Dec 31, 2018 | $6.99 | $6.72 | $6.01 - $7.65 | +4.02% | Beat | +32.9% | 26 | N/A | Jan 29, 2019 | $3.53B |
| Sep 30, 2018 | $7.40 | $6.76 | $6.53 - $7.19 | +9.47% | Beat | +17.3% | 26 | N/A | Oct 23, 2018 | $3.44B |
| Jun 30, 2018 | $5.80 | $5.14 | $3.95 - $6.44 | +12.84% | Beat | +15.1% | 26 | N/A | Jul 24, 2018 | $3.36B |
| Mar 31, 2018 | $6.05 | $5.94 | $5.54 - $6.26 | +1.85% | Beat | +16.3% | 26 | N/A | Apr 24, 2018 | $3.13B |
| Dec 31, 2017 | $5.26 | $5.45 | $4.82 - $6.08 | -3.49% | Miss | +4.4% | 30 | N/A | Jan 25, 2018 | $3.31B |
| Sep 30, 2017 | $6.31 | $5.72 | $5.10 - $6.16 | +10.31% | Beat | +21.6% | 26 | N/A | Oct 24, 2017 | $3.08B |
| Jun 30, 2017 | $5.04 | $4.37 | $3.92 - $5.58 | +15.33% | Beat | -3.3% | 25 | N/A | Jul 25, 2017 | $3.08B |
| Mar 31, 2017 | $5.20 | $4.97 | N/A | +4.63% | Beat | +8.6% | N/A | N/A | Apr 25, 2017 | $2.81B |
| Dec 31, 2016 | $5.04 | $4.96 | N/A | +1.61% | Beat | +12.0% | N/A | N/A | Jan 26, 2017 | $2.87B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $15.29, down 7.2% from the year before. It was $20.23 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $15.29 | -7.2% |
| Dec 31, 2024 | $16.47 | +9.2% |
| Dec 31, 2023 | $15.08 | -14.8% |
| Dec 31, 2022 | $17.69 | -7.8% |
| Dec 31, 2021 | $19.18 | -41.6% |
| Dec 31, 2020 | $32.82 | -2.4% |
| Dec 31, 2019 | $33.64 | +28.2% |
| Dec 31, 2018 | $26.24 | +20.3% |
| Dec 31, 2017 | $21.81 | +7.8% |
| Dec 31, 2016 | $20.23 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 21 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,485 | 21 | |
| 2026Q2 | Jun 30, 2026 | 10,275 | 17 | |
| 2026Q1 | Mar 31, 2026 | 9,098 | 18 | |
| 2025Q4 | Dec 31, 2025 | 9,520 | 17 | |
| 2025Q3 | Sep 30, 2025 | 7,937 | 16 | |
| 2025Q2 | Jun 30, 2025 | 6,427 | 14 | |
| 2025Q1 | Mar 31, 2025 | 7,379 | 14 | |
| 2024Q4 | Dec 31, 2024 | 5,817 | 15 |
2026Q3 Earnings Call
Opening remarks
Tim Power Head of Investor Relations Thanks, Cynthia. Good morning, everybody. Welcome to Biogen's third quarter 2026 earnings call. During this call, we will make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide you with a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results, as well as reconciliations between GAAP and non-GAAP results discussed on this call, can be found in the Investors section of biogen.com. We have also posted the slides to our website that we will use during the call. On today's call, I am joined by our President and Chief Executive Officer, Christopher A. Viehbacher; Dr. Priya Singhal, Head of Development; Robin Kramer, our Chief Financial Officer; and Alisha Alaimo, President, North America, who is also available for the Q&A section of the call. Christopher will make some opening comments, and we will move to the Q&A session. To allow us to get through as many questions as possible, we will ask you to kindly limit yourself to just one question. I will now hand the call over to Christopher.
Christopher A. Viehbacher President and CEO All right. Thank you, Tim. Good morning, everybody. A very strong quarter this morning. It is actually one of those quarters where the numbers almost speak for themselves. Total revenue grew 11% year over year. Now, of course, that is not all organic. That was significantly benefited by the acquisition of Apellis. But I would also say that the acquisition and integration of Apellis has gone even better than expected. The integration team has, I think, been able to identify and realize cost synergies faster than we thought. Alisha is here, and I have to give her a lot of credit for her leadership in really ensuring that the Apellis team has felt welcome within Biogen. I think the most credit goes to the people from Apellis who have joined Biogen, placed their faith in Biogen, and have been able to look past the inevitable distraction that comes with an integration and really focus on our customers, the health care professionals, and patients that we serve. So, as I look at it, obviously, Apellis has certainly helped us. Our industry has embraced bolt-on acquisitions over the years. But one of the things I have learned is that if you are going to do a bolt-on, you have to bolt it on to something solid. One of the things that we have been working on at Biogen over the last several years is improving our cost base, but also really launching our growth products and getting those performing at a top level.
Frequently Asked Questions About BIIB
When is Biogen's next earnings date?
Biogen's next earnings report is expected for Feb 4, 2027.
Did BIIB beat earnings estimates last quarter?
Yes. Biogen reported EPS of $2.62 for the quarter ended Sep 30, 2026, above the $2.06 estimate, a 27.18% surprise.
What EPS do analysts expect from BIIB next quarter?
The consensus EPS estimate for Biogen for the quarter ending Dec 31, 2026 is $2.81 from 33 analysts, with estimates from $2.39 to $3.45.
How often does BIIB beat earnings estimates?
Biogen beat the EPS estimate in each of the last 18 quarters, with an average surprise of +16.18%.
BIIB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors